Pasar al contenido principal

EL PAPEL DE ADAMTS2 EN ESQUIZOFRENIA: NUEVOS CONOCIMIENTOS SOBRE MECANISMOS CEREBRALES IMPLICADOS Y PERSPECTIVAS TERAPEUTICAS BASADO EN MODELOS CELULARES Y ANIMALES.

PID2019-109405RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Exploratory Analysis of MicroRNA Alterations in a Neurodevelopmental Mouse Model for Autism Spectrum Disorder and Schizophrenia

  • García-Cerro, Susana
  • Gómez-Garrido, Ana
  • Garcia, Gonçalo
  • Crespo-Facorro, Benedicto
  • Brites, Dora
MicroRNAs (miRNAs) play a crucial role in the regulation of gene expression levels and have been implicated in the pathogenesis of autism spectrum disorder (ASD) and schizophrenia (SCZ). In this study, we examined the adult expression profiles of specific miRNAs in the prefrontal cortex (PFC) of a neurodevelopmental mouse model for ASD and SCZ that mimics perinatal pathology, such as NMDA receptor hypofunction, and exhibits behavioral and neurophysiological phenotypes related to these disorders during adulthood. To model the early neuropathogenesis of the disorders, mouse pups were administered subcutaneously with ketamine (30 mg/Kg) at postnatal days 7, 9, and 11. We focused on a set of miRNAs most frequently altered in ASD (miR-451a and miR-486-3p) and in SCZ (miR-132-3p and miR-137-3p) according to human studies. Additionally, we explored miRNAs whose alterations have been identified in both disorders (miR-21-5p, miR-92a-2-5p, miR-144-3p, and miR-146a-5p). We placed particular emphasis on studying the sexual dimorphism in the dynamics of these miRNAs. Our findings revealed significant alterations in the PFC of this ASD- and SCZ-like mouse model. Specifically, we observed upregulated miR-451a and downregulated miR-137-3p. Furthermore, we identified sexual dimorphism in the expression of miR-132-3p, miR-137-3p, and miR-92a-2-5p. From a translational perspective, our results emphasize the potential involvement of miR-92a-2-5p, miR-132-3p, miR-137-3p, and miR-451a in the pathophysiology of ASD and SCZ and strengthen their potential as biomarkers and therapeutic targets of such disorders., This work was funded by an unrestricted research funding from Spanish Network for Research in Mental Health (CIBERSAM, G26) and PI22_01379 by the Carlos III Health Institute to B.C.-F., the Spanish State Research Agency (PID2019-109405R) to B.C.-F., the Andalusian Plan for Research, Development, and Innovation (P20_00811, PI-0014-2022) to B.C.-F., the Fundação para a Ciência e a Tecnologia (PTDC/MED-NEU/2382/2021, LISBOA-01-0145-FEDER-031395, UIDB/04138/2020, UIDP/04138/2020) to D.B., and La Caixa Foundation-Luzón Foundation (HR21-00931) to D.B. S.G.-C. is supported by a Sara Borrell contract (CD19_00183) and a M-AES mobility grant (MV22/00107) provided by the Carlos III Health Institute. A.G.-G. is supported by a predoctoral contract provided by the Andalusian System of Knowledge (PREDOC_02201). G.G. is supported by a Farm-ID contract (5/2022/PTDC/MED-NEU/2382/2021)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Shared molecular signature in Alzheimer's disease and schizophrenia: A systematic review of the reelin signaling pathway

  • Valderrama-Mantilla, Ana Isabel
  • Martín-Cuevas, Celia
  • Gómez-Garrido, Ana
  • Morente-Montilla, Cristina
  • Crespo-Facorro, Benedicto
  • García-Cerro, Susana
The Reelin signaling pathway, particularly the RELN-APOER2-DAB1 complex, has emerged as a key contributor to the neuropathology of Alzheimer's disease (AD) and Schizophrenia (SZ). Despite being distinct clinical conditions, these disorders exhibit similar patterns of cognitive decline, including early disruptions in synaptic function and memory impairments. Notably, individuals with SZ have a 2-4 fold increased risk of developing AD or other dementias, highlighting potential shared molecular mechanisms, and positioning Reelin as a pivotal link between them. This systematic review explores the role of Reelin and its signaling components across these disorders. In AD, Reelin disruption correlates with hallmark features such as Tau hyperphosphorylation, amyloid-beta accumulation, and cognitive deficits. In SZ, alterations in Reelin signaling, including epigenetic modifications affecting RELN expression, are linked to disruptions in neuronal development and synaptic plasticity, particularly in the parietal and prefrontal cortices. Additionally, genomic studies reveal specific RELN variants and allelic imbalances that may influence disease severity and treatment response in SZ, suggesting RELN's role as a potential biomarker for therapeutic outcomes. Region-specific Reelin alterations in both AD and SZ suggest differing impacts yet underscore a potential common molecular origin. Our findings highlight the Reelin pathway as a molecular convergence point, warranting further investigation as a therapeutic and diagnostic target for AD, SZ, and potentially other neuropsychiatric disorders. The interplay between genetic and epigenetic regulation of RELN may provide novel insights into neurodegeneration, with implications for personalized intervention strategies in AD and SZ., This work was supported by PID2019-109405RB-I00 / AEI / 10.13039/501100011033; the Andalusian Plan for Research, Development, and Innovation and ERDF/EU through project P20_00811 and fellowship PREDOC_02201; the Regional Ministry of Health (Junta de Andalucía) through project PI-0014-2022; the Instituto de Salud Carlos III (ISCIII) co-funded by the European Union, through projects AC23_2/00034 and PI22/01379, the Sara Borrell fellowship (CD19_00183), the M-AES mobility grant (MV22/00107), and unrestricted research funding from the Spanish Network for Research in Mental Health (CIBERSAM, G26). AIV-M did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sector. CM-C and CM-M were supported by the Instituto de Salud Carlos III (AC23_2/00034 and FI23/00221, respectively). AG-G was supported by a predoctoral contract of the Andalusian System of Knowledge (PREDOC_02201). BC-F received unrestricted research funding from Instituto de Salud Carlos III, MINECO, Gobierno de Cantabria, Spanish Network for Research in Mental Health (CIBERSAM), from the Seventh European Union Framework Program and Lundbeck. He has also received honoraria for his participation as a consultant and/or as a speaker at educational events from Janssen Johnson and Johnson, Mylan, Lundbeck, and Otsuka Pharmaceuticals. SG-C was supported by a Sara Borrell contract (CD19_00183) provided by the Carlos III Health Institute., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Metabolic dysfunction-associated steatotic liver disease alters brain function and behavior: Insights from liver-targeted siRNA therapy

  • Cardoso Delgado, Teresa de Jesús
  • Martín-Cuevas, Celia
  • Sánchez-Hidalgo, Ana C.
  • Gil-Gómez, Antonio
  • Rejano-Gordillo, Claudia María
  • Landa, Jon
  • Gallego-Durán, Rocío
  • Goikoetxea-Usandizaga, Naroa
  • González-Recio, Irene
  • Gil-Pitarch, Clàudia
  • Zapata-Pavas, L. Estefanía
  • Barrenechea-Barrenechea, Jon Ander
  • Conter, Carolina
  • Martínez-Cruz, Luis Alfonso
  • Ramos Herrero, Víctor
  • Nogueiras, Rubén
  • Azkargorta, Mikel
  • Elortza, Félix
  • Moncho-Amor, Verónica
  • Crespo, Javier
  • Matheu, Ander
  • Romero-Gómez, Manuel
  • Crespo-Facorro, Benedicto
  • Martínez-Chantar, María Luz
[Data and materials availability:] The mass spectrometry proteomics data have been deposited in the ProteomeXchange Consortium via the PRIDE [1] partner repository with the dataset identifier PXD063321 (www.ebi.ac.uk/pride/archive/projects/PXD063321). All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials., Metabolic dysfunction–associated steatotic liver disease (MASLD), a liver-centric condition, is associated with cognitive impairment and sensorimotor alterations. However, it remains unclear whether MASLD is sufficient to drive central nervous system deficits. Here, using diet-induced mouse models, we showed that MASLD was associated with alterations in social memory, sensorimotor processing, and hippocampal function, including decreased parvalbumin-positive interneurons, reduced dendritic spine density, and diminished dentate gyrus neurogenesis and neuronal differentiation. Then, we selectively modulated liver metabolism through N-acetylgalactosamine small interfering RNA (siRNA) therapy against Cyclin M4 (CNNM4), a magnesium transporter dysregulated in MASLD. Liver-specific intervention with siRNA-Cnnm4 reversed impaired social memory and sensorimotor processing in association with recovery of hippocampal synaptogenesis and mitochondrial function pathways, alongside activation of neurogenesis-associated transcriptional programs. Our findings demonstrate that liver pathology is sufficient to drive neurobehavioral and hippocampal dysfunction in MASLD. Hepatic-specific intervention restores brain function, strongly supporting the existence of a causal and therapeutically targetable liver-brain axis for MASLD-associated neurological complications., This work was supported by grants from Ministerio de Ciencia, Innovación y Universidades MICINN: CEX2021-001136-S (to M.L.M.-C.) and MICINN: PID2022-139395OB-100 (to M.L.M.-C.); integrado en el Plan Estatal de Investigación Científica y Técnica e Innovación, cofinanciado con Fondos FEDER; and Project funded by CIBEREHD; 2018 BBVA Foundation Grants for Scientific Research Teams- UMBRELLA (to M.L.M.-C., M.R.G., and B.C.-F.). T.C.D. is funded by “Ayuda RYC2020-029316-I financiada por MCIN/AEI/10.13039/501100011033 y por El FSE invierte en tu futuro.” This work was supported by grants from Ministerio de Ciencia, Innovación y Universidades MICINN: PID2020-117116OB-I00 (to T.C.D.). C.M.-C. was supported by CIBERSAM (G26) and the Instituto de Salud Carlos III (AC23_2/00034). A.C.S.H. received funding from CIBERSAM (G26) and the Consejería de Salud y Familias (RH-0063). V.D.R.H. was supported by the Agencia Estatal de Investigación (PID2019-109405R and PI-0014-2022). L.E.Z.-P. was supported by a PhD fellowship from the Provincial Section of Bizkaia from the Scientific Foundation of the Spanish Association Against Cancer PRDVZ233980ZAPA. C.M.R.G. was supported by Ayuda Juan de la Cierva JDC2023-052761-I from the MCIN/AEI/10.13039/501100011033–Unión Europea NextGenerationEU/PRTR. V.M.-A. was supported by the Miguel Servet contract (CP23/00111) from the ISCIII. This project has also received funding from the European Horizon’s research and innovation program HORIZON-HLTH-2022-STAYHLTH-02 (agreement no. 101095679), Spanish Instituto de Salud Carlos III-FEDER Grant (FIS-PI22/01853) and European Union-NextGenerationEU (PMP21/00112) (to J.C.)., With funding form the Spanish government through the "Severa Ochoa Centre of Excellence" accreditation (CEX2021-001136-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Clozapine induces perineuronal net remodeling in a developmental mouse model exhibiting schizophrenia-relevant phenotypes

  • García-Cerro, Susana
  • Gómez-Garrido, Ana
  • Soria, Federico
  • Loucera, Carlos
  • Crespo-Facorro, Benedicto
Schizophrenia (SCZ) is a multifaceted neurodevelopmental disorder characterized by widespread dysregulation of extracellular matrix (ECM) components, particularly perineuronal nets (PNNs), which are crucial for synaptic stability and cognitive function. Alterations in PNNs, especially in the prefrontal cortex (PFC), have been linked to cognitive deficits in SCZ. While antipsychotic (AP) treatments have been suggested to influence PNNs and ECM integrity, their specific effects remain unclear. In this study, we used a neurodevelopmental mouse model exhibiting SCZ-relevant phenotypes, induced by perinatal NMDA receptor hypofunction through ketamine administration, to investigate the impact of PNN alterations and their modulation by clozapine (CLZ), an atypical AP, in adulthood. We found that ketamine exposure led to increased PNN thickness and reduced structural complexity (i.e., more compact and less porous PNNs), elevated VGLUT1-mediated excitatory inputs, and dysregulated medial PFC network activity, characterized by hyperactivation of surviving PV interneurons and a disrupted excitation/inhibition balance. Treatment with CLZ mitigated these changes by partially restoring PNN microarchitecture and enhancing the structural integrity and porosity of PNNs in the medial PFC. Additionally, CLZ-mediated effects on PNNs were associated with improvements in cognitive flexibility and social memory, functions tightly linked to PFC-dependent processing. These findings suggest that CLZ’s actions on PNN structure may contribute to its therapeutic effects in conditions involving prefrontal cortical dysfunction, as observed in SCZ, although these correlations require further investigation to confirm their causal relevance. Overall, our results underscore the need for further investigation into the impact of AP medications on PNN plasticity and ECM integrity., This work was supported by the Spanish State Research Agency and European Union NextGenerationEU/PRTR through project PID2019-109405R and grant RYC2021-032602-I; the Andalusian Plan for Research, Development, and Innovation and ERDF/EU through project P20_00811 and fellowship PREDOC_02201; and the Instituto de Salud Carlos III (ISCIII) co-funded by the European Union, through project PI22/01379, the Sara Borrell fellowship (CD19_00183), the M-AES mobility grant (MV22/00107), and unrestricted research funding from the Spanish Network for Research in Mental Health (CIBERSAM, G26)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mitochondrial signals in the bloodstream: Peripheral signature of mitochondrial dysfunction in mental health. A systematic review

  • Fernández-Pech, Inés Lucía
  • Fernández-Guillén, María
  • Morente-Montilla, Cristina
  • Crespo-Facorro, Benedicto
  • Martín-Cuevas, Celia
Psychiatric disorders are characterized by marked clinical heterogeneity, overlapping symptom dimensions, and the persistent lack of objective biomarkers. Liquid biopsy has emerged as a promising, non-invasive strategy to identify peripheral molecular signatures that may inform diagnosis and treatment monitoring. Given the central involvement of mitochondrial dysfunction in psychiatric pathophysiology, circulating cell-free mitochondrial DNA (ccf-mtDNA) has attracted increasing interest as a candidate biomarker. Following PRISMA 2020 guidelines, this systematic review synthesized evidence on ccf-mtDNA alterations in bipolar disorder (BD), depressive disorders (DD), and schizophrenia (SCZ). Findings in BD were heterogeneous: several studies reported elevated ccf-mtDNA, particularly in unmedicated individuals and those with cognitive deficits, whereas others observed no differences or even decreased levels compared with healthy controls (HC). In DD, evidence more consistently indicated increased ccf-mtDNA, especially in unmedicated or late-life depression, where higher levels correlated with symptom severity, frailty, and inflammatory indices. These data support ccf-mtDNA as a peripheral marker of mitochondrial and inflammatory dysregulation in DD. Conversely, most studies in SCZ reported no significant differences relative to HC; however, elevated ccf-mtDNA levels observed in cognitively impaired subgroups and in patients exhibiting alterations in brain bioenergetics point to underlying clinical and biological heterogeneity. Collectively, current evidence implicates ccf-mtDNA as a putative biomarker of mitochondrial dysfunction in psychiatry, with greater translational potential in DD and BD. Nonetheless, methodological heterogeneity, small sample sizes, and cross-sectional designs underscore the need for standardized, longitudinal investigations to establish its diagnostic and prognostic validity., This work was supported by the Consejería de Conocimiento y Universidades through project PID2019–109405RB-I00 / AEI / 10.13039/501100011033; the Andalusian Plan for Research, Development, and Innovation and ERDF/EU through project P20_00811; the Regional Ministry of Health (Junta de Andalucía) through project PI-0014–2022; the Instituto de Salud Carlos III (ISCIII) co-funded by the European Union, through projects AC23_2/00034 and PI22/01379, and unrestricted research funding from the Spanish Network for Research in Mental Health (CIBERSAM, G26). ILF-P did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sector. MF-G was supported by the Spanish Network for Research in Mental Health (CIBERSAM). CM-M was supported by a predoctoral contract of the Instituto de Salud Carlos III (FI23/00221). BC-F received unrestricted research funding from Instituto de Salud Carlos III, MINECO, Gobierno de Cantabria, Spanish Network for Research in Mental Health (CIBERSAM), from the Seventh European Union Framework Program and Lundbeck. He has also received honoraria for his participation as a consultant and/or as a speaker at educational events from Janssen Johnson and Johnson, Mylan, Lundbeck, and Otsuka Pharmaceuticals. CM-C was supported by the Instituto de Salud Carlos III (AC23_2/00034)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Convergent blood–brain barrier breakdown in schizophrenia and autism spectrum disorders: a systematic review of preclinical animal models

  • Morente-Montilla, Cristina
  • Fernández-Guillén, María
  • Gómez-Garrido, Ana
  • García-Cerro, Susana
  • Moreno-Mellado, Amanda
  • Campbell, Matthew
  • Soreq, Hermona
  • Greenberg, David S.
  • Deli, Maria A.
  • Crespo-Facorro, Benedicto
  • Martín-Cuevas, Celia
  • Riga, Maurizio S.
[Background] Schizophrenia (SCZ) and autism spectrum disorder (ASD) are neurodevelopmental disorders with multifactorial origins involving genetic and environmental risk factors. Both conditions share overlapping pathophysiological mechanisms, including neuroinflammation, synaptic dysfunction, and circuit-level disturbances. Emerging evidence implicates blood-brain barrier (BBB) dysfunction as a potential common element in their pathogenesis. Specifically, BBB disruption is a recurring feature in preclinical models of SCZ and ASD, suggesting its role as a transdiagnostic mechanism in neurodevelopmental disorders. This systematic review aims to evaluate BBB alterations-including permeability, integrity, developmental changes, and tight junction (TJ) protein expression-in rodent models of SCZ- and ASD-like phenotypes., [Methods] Following PRISMA guidelines, we screened experimental studies assessing BBB status in murine models of SCZ and ASD compared to wild type rodents. Inclusion criteria focused on models based on genetic manipulation and environmental insults. Included studies consistently reported BBB alterations across diverse models., [Results] Findings showed disrupted TJ protein expression (claudin-5, occludin, ZO-1), increased permeability, and endothelial dysfunction. Both genetic (e.g., Shank3, 22q11.2 deletion, etc.) and environmental (e.g., maternal immune activation, valproate exposure, etc.) models exhibited BBB abnormalities. Pharmacological and experimental interventions targeting the BBB—such as claudin-5 modulation or β-catenin signaling—ameliorated BBB damage and behavioral phenotypes., [Conclusions] That BBB disruption is a recurring feature in preclinical models of SCZ and ASD suggests its pursuit as a transdiagnostic mechanism in neurodevelopmental disorders. However, as many findings rely on single studies, further replication is essential. Future studies should explore sex differences, critical developmental windows, and therapeutic strategies aimed at restoring BBB function., This work was supported by the Consejería de Conocimiento y Universidades through project PID2019-109405RB-I00/AEI/10.13039/501100011033; the Andalusian Plan for Research, Development, and Innovation and ERDF/EU through project P20_00811 and fellowship PREDOC_02201; the Regional Ministry of Health (Junta de Andalucía) through project PI-0014-2022; the Instituto de Salud Carlos III (ISCIII) co-funded by the European Union, through projects AC23_2/00034 and PI22/01379; and unrestricted research funding from the Spanish Network for Research in Mental Health (CIBERSAM, G26). CM-M was supported by a predoctoral contract of the Instituto de Salud Carlos III (FI23/00221). MF-G was supported by the Spanish Network for Research in Mental Health (CIBERSAM). AG-G was supported by a predoctoral contract of the Andalusian System of Knowledge (PREDOC_02201). SG-C was supported by a Sara Borrell contract (CD19_00183) provided by the Carlos III Health Institute, and the M-AES mobility grant (MV22/00107). AM-M was supported by the Instituto de Salud Carlos III (PMP21/00085). BC-F received unrestricted research funding from Instituto de Salud Carlos III, MINECO, Gobierno de Cantabria, Spanish Network for Research in Mental Health (CIBERSAM), from the Seventh European Union Framework Program and Lundbeck., MC is supported by Taighde Éireann – Research Ireland, under Grant numberEye-D-21/SPP/3732 and 21/RC/10294_P2 at FutureNeuro Research Ireland Centre for Translational Brain Science. The lab is also supported by a grant from the European Research Council (ERC – Retina-Rhythm) and ERA NET NEURON B3phrenia grant. HS is supported by ERA NET NEURON B3phrenia grant and Israel Science Foundation grant 835/23. MAD is supported by the National Research, Development and Innovation Office of Hungary (K143766; 2024-1.2.2-ERA_NET-2024-00018) and the Hungarian Academy of Sciences (NAP2022-I-6/2022). CM-C was supported by the Instituto de Salud Carlos III (AC23_2/00034). MS-R was supported by the Spanish Network for Research in Mental Health (CIBERSAM)., Peer reviewed